Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| smooth muscle cell | 19 studies | 38% ± 16% | |
| pericyte | 13 studies | 39% ± 19% | |
| ciliated cell | 12 studies | 52% ± 17% | |
| fibroblast | 7 studies | 34% ± 17% | |
| mesothelial cell | 6 studies | 56% ± 12% | |
| connective tissue cell | 4 studies | 25% ± 5% | |
| myofibroblast cell | 4 studies | 20% ± 3% | |
| chondrocyte | 3 studies | 54% ± 30% | |
| myoepithelial cell | 3 studies | 66% ± 15% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| lung | 3 studies | 21% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| thymus | 99% | 3429.55 | 648 / 653 | 88% | 235.88 | 534 / 605 |
| prostate | 89% | 1779.68 | 217 / 245 | 90% | 22.97 | 453 / 502 |
| breast | 93% | 1573.52 | 428 / 459 | 32% | 8.74 | 362 / 1118 |
| kidney | 75% | 1280.15 | 67 / 89 | 39% | 6.78 | 350 / 901 |
| uterus | 86% | 1285.09 | 146 / 170 | 17% | 5.55 | 78 / 459 |
| bladder | 90% | 2428.48 | 19 / 21 | 11% | 1.63 | 53 / 504 |
| blood vessel | 99% | 3383.15 | 1318 / 1335 | 0% | 0 | 0 / 0 |
| stomach | 78% | 4644.16 | 279 / 359 | 19% | 8.26 | 54 / 286 |
| lung | 70% | 769.76 | 404 / 578 | 23% | 4.67 | 270 / 1155 |
| adipose | 92% | 1859.47 | 1110 / 1204 | 0% | 0 | 0 / 0 |
| esophagus | 78% | 2451.43 | 1131 / 1445 | 13% | 1.71 | 24 / 183 |
| ovary | 23% | 298.96 | 42 / 180 | 65% | 20.44 | 279 / 430 |
| intestine | 72% | 1039.28 | 698 / 966 | 11% | 3.25 | 56 / 527 |
| adrenal gland | 30% | 241.36 | 77 / 258 | 52% | 16.30 | 120 / 230 |
| brain | 26% | 165.67 | 680 / 2642 | 50% | 7.59 | 354 / 705 |
| spleen | 68% | 653.88 | 164 / 241 | 0% | 0 | 0 / 0 |
| pancreas | 2% | 10.13 | 7 / 328 | 37% | 4.09 | 66 / 178 |
| skin | 28% | 188.52 | 510 / 1809 | 9% | 2.28 | 43 / 472 |
| heart | 32% | 258.62 | 279 / 861 | 0% | 0 | 0 / 0 |
| muscle | 12% | 66.30 | 96 / 803 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 7% | 1.75 | 3 / 45 |
| liver | 1% | 7.27 | 3 / 226 | 3% | 0.20 | 11 / 406 |
| eye | 0% | 0 | 0 / 0 | 1% | 0.09 | 1 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0090398 | Biological process | cellular senescence |
| GO_0031145 | Biological process | anaphase-promoting complex-dependent catabolic process |
| GO_0070314 | Biological process | G1 to G0 transition |
| GO_0042127 | Biological process | regulation of cell population proliferation |
| GO_0007417 | Biological process | central nervous system development |
| GO_0016324 | Cellular component | apical plasma membrane |
| GO_0005615 | Cellular component | extracellular space |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005515 | Molecular function | protein binding |
| Gene name | ECRG4 |
| Protein name | Augurin (Esophageal cancer-related gene 4 protein) (ECRG4) ECRG4 augurin precursor Alternative protein C2orf40 |
| Synonyms | UNQ761/PRO1508 C2orf40 |
| Description | FUNCTION: Probable hormone that may attenuate cell proliferation and induce senescence of oligodendrocyte and neural precursor cells in the central nervous system (By similarity). ECRG4-induced senescence is characterized by G1 arrest, RB1 dephosphorylation and accelerated CCND1 and CCND3 proteasomal degradation (By similarity). . |
| Accessions | ENST00000409944.5 Q9H1Z8 C9JRR0 ENST00000437659.1 B8ZZE5 L8E9F0 ENST00000238044.8 |
